|1.||Cassiman, David: 1 article (01/2009)|
|2.||Jaeken, Jaak: 1 article (01/2009)|
|3.||Zeevaert, Renate: 1 article (01/2009)|
|4.||Holme, Elisabeth: 1 article (01/2009)|
|5.||Kvittingen, Eli-Anne: 1 article (01/2009)|
01/01/2009 - " is the first report of mild tyrosinemia type I disease caused by an Ala35Thr mutation in the FAH gene, presenting atypically without increase of the diagnostically important toxic metabolites succinylacetone and succinylacetoacetate."
01/01/1981 - "On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone."
10/01/1982 - "Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia."
01/01/2009 - "In urine, tyrosine metabolites and 4-oxo-6-hydroxyheptanoic acid were increased, but succinylacetone and succinylacetoacetate--pathognomonic for tyrosinemia type I--were repeatedly undetectable. "
01/01/1981 - "Phenylalanine and homogentisate increase the concentration of succinylacetoacetate and succinylacetone both in serum and urine in patients with hereditary tyrosinemia and therefore increase the excretion of 5-aminolevulinate. "
|5.||Aminolevulinic Acid (Levulan)